Industry Newsvaccinesclinical trialsvaxcyte
Vaxcyte Receives Bullish Analyst Buy Rating
6.0
BTIG analyst Thomas Shrader reiterated a Buy rating for Vaxcyte on Dec. 9, setting an $85 target, implying about 83% upside. He cited positive Phase 2 results for the VAX-31 vaccine and a rigorous Phase 3 noninferiority design targeting adults 50–65. As of Dec. 19, all seven analyst ratings were Buy, with a median 1-year target of $100.80 (about 117% upside).
Key Points
- 1Assigns Buy rating with $85 target implying greater than 83% upside from current levels
- 2Cites positive Phase 2 VAX-31 results and rigorous Phase 3 noninferiority design as clinical validation
- 3Highlights adults 50–65 target market, suggesting substantial adoption potential and competitive positioning for VAX-31
Scoring Rationale
Analyst-backed Phase 2 data and unanimous Buy consensus bolster impact; limited by niche biotech relevance outside AI/ML.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
